pharmasset results, page-3

Nice summary Jossette.

...and what did Dr Stephen Griffin
Antivirals & Viral Oncology Group Leader
Section of Oncology and Clinical Research
Leeds Institute of Molecular Medicine
St James's University Hospital

say in 2009 about the class of drug that Pharmasset was developing....

"Drugs targeting the viral protease and polymerase are forthcoming, yet evidence already suggests that the virus rapidly becomes resistant where these drugs are used alone, just as seen for the first HIV patients receiving AZT"

...and what did Dr. Michelle Miller say about the type of drug Pharmasset had developed in Nov.2011 ?

"It is also worth noting that drugs of the class that Pharmasset is targeting tend to have a high rate of generation of resistance i.e. the drugs can rapidly become ineffective".

...and what did Dr, Michelle Miller say about Biotron's BIT-225 ?

"To date, that has not been our experience with BIT225, which is to be expected due to its mode of action"

Back up the truck!!!
GLTA FF